Renal vein

Results: 49



#Item
21Cardiovascular and Renal Drugs Advisory Committee September 8, 2011 NDA[removed]Dose Selection

Cardiovascular and Renal Drugs Advisory Committee September 8, 2011 NDA[removed]Dose Selection

Add to Reading List

Source URL: www.fda.gov

Language: English
22Winter[removed]Vascular Cures is changing the way we care for patients by developing treatments that address the unique genetic and biological makeup of each person. We’re building the first national biobank of blood and

Winter[removed]Vascular Cures is changing the way we care for patients by developing treatments that address the unique genetic and biological makeup of each person. We’re building the first national biobank of blood and

Add to Reading List

Source URL: vascularcures.org

Language: English - Date: 2012-03-05 14:33:25
23Adopted: September 1, 2010  IOWA STATE UNIVERSITY Institutional Animal Care and Use Committee Blood Collection Guidelines Purpose

Adopted: September 1, 2010 IOWA STATE UNIVERSITY Institutional Animal Care and Use Committee Blood Collection Guidelines Purpose

Add to Reading List

Source URL: www.compliance.iastate.edu

Language: English - Date: 2010-09-14 13:27:23
24HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use GAMMAGARD S/D safely and effectively. See full prescribing information for GAMMAGARD S/D GAMMAGARD S/D, Immune Globu

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use GAMMAGARD S/D safely and effectively. See full prescribing information for GAMMAGARD S/D GAMMAGARD S/D, Immune Globu

Add to Reading List

Source URL: www.fda.gov

Language: English
25Cardiovascular and Renal Drugs Advisory Committee Meeting Briefing Bypass Graft Failure as a Clinical Endpoint for CABG Patients CARDIOVASCULAR AND RENAL DRUGS ADVISORY COMMITTEE BRIEFING DOCUMENT December 8, 2010

Cardiovascular and Renal Drugs Advisory Committee Meeting Briefing Bypass Graft Failure as a Clinical Endpoint for CABG Patients CARDIOVASCULAR AND RENAL DRUGS ADVISORY COMMITTEE BRIEFING DOCUMENT December 8, 2010

Add to Reading List

Source URL: www.fda.gov

Language: English
26DIVISION OF CARDIO-RENAL DRUG PRODUCTS

DIVISION OF CARDIO-RENAL DRUG PRODUCTS

Add to Reading List

Source URL: www.fda.gov

Language: English
27Rivaroxaban (XARELTO®)                            Cardiovascular and Renal Drugs Advisory Committee  January 16, 2014

Rivaroxaban (XARELTO®)                           Cardiovascular and Renal Drugs Advisory Committee  January 16, 2014

Add to Reading List

Source URL: www.fda.gov

Language: English
28------------------------------- CONTRAINDICATIONS -----------------------ARIXTRA is contraindicated in the following conditions: (4) • Severe renal impairment (creatinine clearance <30 mL/min) in prophylaxis or treatme

------------------------------- CONTRAINDICATIONS -----------------------ARIXTRA is contraindicated in the following conditions: (4) • Severe renal impairment (creatinine clearance <30 mL/min) in prophylaxis or treatme

Add to Reading List

Source URL: www.accessdata.fda.gov

Language: English - Date: 2014-07-17 13:21:13
29Maturation of Arteriovenous Fistulas Placed Prior to Dialysis Initiation Craig Solid, PhD, Robert Foley, MB United States Renal Data System, Minneapolis Medical Research Foundation, University of Minnesota Twin Cities Re

Maturation of Arteriovenous Fistulas Placed Prior to Dialysis Initiation Craig Solid, PhD, Robert Foley, MB United States Renal Data System, Minneapolis Medical Research Foundation, University of Minnesota Twin Cities Re

Add to Reading List

Source URL: www.usrds.org

Language: English - Date: 2012-11-16 15:14:54
30Cannulation Techniques Webinar March 28, 2012 ESRD Network of Texas Lynda K. Ball, MSN, RN, CNN

Cannulation Techniques Webinar March 28, 2012 ESRD Network of Texas Lynda K. Ball, MSN, RN, CNN

Add to Reading List

Source URL: www.esrdnetwork.org

Language: English - Date: 2013-10-12 17:16:40